FIORINAL
LOE ApproachingNDAORALTABLET
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIORINAL is an oral tablet small-molecule product approved in 1976 by AbbVie. The specific indication and mechanism of action are not documented in available data. This legacy product represents a mature therapeutic asset with established clinical utility.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the commercial team is likely consolidating operations and transitioning to lifecycle defense strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FIORINAL offers limited career growth opportunities given its LOE-approaching status and minimal linked job openings. Roles are concentrated in defensive commercial and operational functions focused on maintaining market share and managing the transition.
Brand ManagerCommercial Operations
Worked on FIORINAL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.